Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Jonathan E. Campbell, Daniel J. Drucker
Cell Metabolism (2013) Vol. 17, Iss. 6, pp. 819-837
Open Access | Times Cited: 1283

Showing 1-25 of 1283 citing articles:

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
Cell Metabolism (2018) Vol. 27, Iss. 4, pp. 740-756
Open Access | Times Cited: 1261
Adipokines in health and disease
Mathias Faßhauer, Matthias Blüher
Trends in Pharmacological Sciences (2015) Vol. 36, Iss. 7, pp. 461-470
Closed Access | Times Cited: 924
The role of the gut microbiota in NAFLD
Christopher Leung, Leni R. Rivera, John B. Furness, et al.
Nature Reviews Gastroenterology & Hepatology (2016) Vol. 13, Iss. 7, pp. 412-425
Closed Access | Times Cited: 856
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Fabio Marra, Gianluca Svegliati‐Baroni
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 280-295
Closed Access | Times Cited: 696
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 143-155
Closed Access | Times Cited: 676
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan, Bin Yang, Nickki Ottaway, et al.
Nature Medicine (2014) Vol. 21, Iss. 1, pp. 27-36
Closed Access | Times Cited: 558
Heart Failure in Type 2 Diabetes Mellitus
Helena Kenny, E. Dale Abel
Circulation Research (2019) Vol. 124, Iss. 1, pp. 121-141
Open Access | Times Cited: 543
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Erin E. Mulvihill, Daniel J. Drucker
Endocrine Reviews (2014) Vol. 35, Iss. 6, pp. 992-1019
Open Access | Times Cited: 529
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
Cell Metabolism (2016) Vol. 24, Iss. 1, pp. 15-30
Open Access | Times Cited: 525
GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK
Daniel Beiroa, Mónica Imbernón, Rosalı́a Gallego, et al.
Diabetes (2014) Vol. 63, Iss. 10, pp. 3346-3358
Open Access | Times Cited: 510
Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB
Robert E. Steinert, Christine Feinle‐Bisset, Lori Asarian, et al.
Physiological Reviews (2016) Vol. 97, Iss. 1, pp. 411-463
Open Access | Times Cited: 489
Mechanisms controlling pancreatic islet cell function in insulin secretion
Jonathan E. Campbell, Christopher B. Newgard
Nature Reviews Molecular Cell Biology (2021) Vol. 22, Iss. 2, pp. 142-158
Open Access | Times Cited: 448
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Darleen A. Sandoval, David A. D’Alessio
Physiological Reviews (2015) Vol. 95, Iss. 2, pp. 513-548
Closed Access | Times Cited: 419
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Matthew J. Armstrong, Diana Hull, Kathy Guo, et al.
Journal of Hepatology (2015) Vol. 64, Iss. 2, pp. 399-408
Open Access | Times Cited: 378
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
Conrad Eng, Caroline K. Kramer, Bernard Zinman, et al.
The Lancet (2014) Vol. 384, Iss. 9961, pp. 2228-2234
Closed Access | Times Cited: 367
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Dominik Dahl, Yukiko Onishi, Paul Norwood, et al.
JAMA (2022) Vol. 327, Iss. 6, pp. 534-534
Open Access | Times Cited: 365
The New Biology and Pharmacology of Glucagon
Timo D. Müller, Brian Finan, Christoffer Clemmensen, et al.
Physiological Reviews (2017) Vol. 97, Iss. 2, pp. 721-766
Closed Access | Times Cited: 334
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
Chris de Graaf, Dan Donnelly, Denise Wootten, et al.
Pharmacological Reviews (2016) Vol. 68, Iss. 4, pp. 954-1013
Open Access | Times Cited: 325
Pancreatic β-cell identity, glucose sensing and the control of insulin secretion
Guy A. Rutter, Timothy J. Pullen, David J. Hodson, et al.
Biochemical Journal (2015) Vol. 466, Iss. 2, pp. 203-218
Closed Access | Times Cited: 319
Cardiovascular Actions of Incretin-Based Therapies
John R. Ussher, Daniel J. Drucker
Circulation Research (2014) Vol. 114, Iss. 11, pp. 1788-1803
Open Access | Times Cited: 319
Recent advances in neuropeptide signaling in Drosophila, from genes to physiology and behavior
Dick R. Nässel, Meet Zandawala
Progress in Neurobiology (2019) Vol. 179, pp. 101607-101607
Closed Access | Times Cited: 309
Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes
Cong Tang, Kashan Ahmed, Andreas Gille, et al.
Nature Medicine (2015) Vol. 21, Iss. 2, pp. 173-177
Closed Access | Times Cited: 307
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan P. Frías, Edward J. Bastyr, Louis Vignati, et al.
Cell Metabolism (2017) Vol. 26, Iss. 2, pp. 343-352.e2
Open Access | Times Cited: 289
Three Pillars for the Neural Control of Appetite
Scott M. Sternson, Anne-Kathrin Eiselt
Annual Review of Physiology (2016) Vol. 79, Iss. 1, pp. 401-423
Closed Access | Times Cited: 283
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Daniel J. Drucker
Diabetes (2013) Vol. 62, Iss. 10, pp. 3316-3323
Open Access | Times Cited: 275
Page 1 - Next Page

Scroll to top